NYSE:CHEChemed Stock Price, Forecast & News

Chemed's stock was trading at $414.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CHE stock has increased by 7.7% and is now trading at $445.93. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Chemed.

Chemed is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for Chemed.

Chemed Co. (NYSE:CHE) announced its earnings results on Tuesday, February, 18th. The company reported $4.22 EPS for the quarter, beating the Zacks' consensus estimate of $4.09 by $0.13. The company earned $522.30 million during the quarter, compared to analysts' expectations of $524.20 million. Chemed had a return on equity of 35.38% and a net margin of 11.35%. Chemed's quarterly revenue was up 14.2% on a year-over-year basis. During the same quarter last year, the business earned $3.35 EPS. View Chemed's earnings history.

Chemed declared a quarterly dividend on Friday, February 21st. Shareholders of record on Monday, March 2nd will be given a dividend of $0.32 per share on Monday, March 23rd. This represents a $1.28 annualized dividend and a yield of 0.29%. The ex-dividend date of this dividend is Friday, February 28th. View Chemed's dividend history.

Chemed issued an update on its FY20 earnings guidance on Tuesday, February, 18th. The company provided earnings per share (EPS) guidance of $16.20-16.50 for the period, compared to the Thomson Reuters consensus estimate of $15.63.

4 analysts have issued 1-year price targets for Chemed's stock. Their forecasts range from $490.00 to $535.00. On average, they expect Chemed's share price to reach $515.00 in the next year. This suggests a possible upside of 15.5% from the stock's current price. View analysts' price targets for Chemed.

Headlines about CHE stock have trended very negative on Wednesday, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Chemed earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutChemed.

Chemed saw a decline in short interest during the month of March. As of March 13th, there was short interest totaling 203,600 shares, a decline of 8.3% from the February 27th total of 222,000 shares. Based on an average trading volume of 86,500 shares, the days-to-cover ratio is currently 2.4 days. Currently, 1.3% of the shares of the stock are short sold. View Chemed's Current Options Chain.

Some companies that are related to Chemed include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), CorVel (CRVL), MEDNAX (MD), R1 RCM (RCM), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG).

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include Home Depot (HD), Altria Group (MO), AT&T (T), AbbVie (ABBV), Chevron (CVX), Walt Disney (DIS), Boeing (BA), CVS Health (CVS), Costco Wholesale (COST) and Cisco Systems (CSCO).

Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."

Chemed's stock is owned by many different institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.02%). Company insiders that own Chemed stock include Andrea R Lindell, David Patrick Williams, Donald E Saunders, Frank E Wood, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Nicholas Michael Westfall, Patrick P Grace, Spencer S Lee, Thomas P Rice and Walter L Krebs. View institutional ownership trends for Chemed.

CHE stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Chemed stock in the last two years include Donald E Saunders, and George J Walsh III. View insider buying and selling activity for Chemed.

Shares of CHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CHE stock can currently be purchased for approximately $445.93.

Chemed has a market capitalization of $7.16 billion and generates $1.94 billion in revenue each year. The company earns $219.92 million in net income (profit) each year or $13.95 on an earnings per share basis. Chemed employs 16,641 workers across the globe. View additional information about Chemed.

The official website for Chemed is http://www.chemed.com/.

Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202-4726. The company can be reached via phone at 513-762-6690.